697results about How to "Increase dose" patented technology

A delivery system for a drug or bioactive agent includes an implantable pump and a delivery conduit that may be implanted in an organ or other tissue (e.g., the central or the peripheral nervous system) of a subject. A sensor is also implanted, and a controller unit receives the sensor output and directs drug delivery from within the patient pump accordingly. The sensor directly measures a primary biochemical material or state in the tissue or organ system, and the monitoring unit effects closed loop feedback control of the pump to achieve a desired end. The end may be the regulation of metabolism or maintenance of a stable metabolic or other state, or may be treatment regimen, e.g., by delivery of a dosage level or distribution of a drug in specific brain or nervous an system tissue. The sensed material may be the agent itself, a metabolite, or a related native material, tissue state or condition.

A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form.

The present invention provides methods and system for managing neurological disorders such as epilepsy. In one embodiment, the method comprises measuring one or more signals from a patient and processing the one or more signals to characterize a patient's propensity for a future seizure. The characterized propensity for the seizure is thereafter used to determine an appropriate action for managing or treating the predicted seizure; and a recommendation is communicated to the patient that is indicative of the appropriate action.

The present invention provides systems and methods for managing epilepsy. In one embodiment, a method of the present invention characterize a patient's propensity for a future epileptic seizure and communicates to the patient and/or a health care provider a therapy recommendation. The therapy recommendation is typically a function of the patient's propensity for the future epileptic seizure.

The present invention provides systems and methods for managing epilepsy. In one embodiment, a method of the present invention characterize a patient's propensity for a future epileptic seizure and facilitates administration of a pharmacological agent. The dosage of the pharmacological agent is typically a function of at least one of the patient's propensity for the future epileptic seizure and time period to seizure.

The present invention provides pharmaceutical compositions for controlled release of pharmaceutically active agents, especially those with a high water solubility, high dose, and/or short half-life. In addition, the present application provides methods for preparing and using such pharmaceutical compositions.

An inhaler for medicament in powder form with an opening intended for inhalation. The powder medicament is arranged in the inhaler in a number of enclosures, each enclosure including a specific dose of medicament. A member is provided for enabling access to the dose of medicament. The member is arranged and designed such that it is able to be inserted inside the enclosure and establish at least one outlet passage, between the interior of the enclosure and the inhalation opening, through which outlet passage the medicament is delivered to the patient upon inhalation.

The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that override the interferon(IFN)-induced cellular defense mechanisms against viral infection. In particular, the present invention relates to screening assays that identify agents which selectively inhibit the interaction between viral proteins containing an interferon sensitivity determining region (ISDR) and IFN-induced PKR protein kinase. The present invention more particularly relates to screening assays that identify agents which selectively inhibit the interaction between hepatitis C virus (HCV) nonstructural 5A protein (NS5A), which contains an ISDR, and IFN-induced PKR protein kinase. The interaction between the viral ISDR and IFN-induced PKR protein kinase results in the override of IFN-induced cellular defense mechanisms to combat viral infection. Therefore the agents identified using the assays of the invention may have utility as antiviral agents.

The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.

The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.

A device for imaging an object, such as for breast imaging, includes a gantry frame having mounted thereon an x-ray source, a source grating, a holder or other place for the object to be imaged, a phase grating, an analyzer grating, and an x-ray detector. The device images objects by differential-phase-contrast cone-beam computed tomography. A hybrid system includes sources and detectors for both conventional and differential-phase-contrast computed tomography.

A method of performing microbeam radiation therapy (MRT) includes delivering a dose only to selected tissue in a target volume (10) with continuous broad beam, first, by interleaving arrays of microplanar beams (30,36) only at the target (10). Administered contrast agents can supplement the effect by preferentially increasing the target dose relative to dose in normal tissue. A broad beam effect is alternatively created using non-interleaving microbeam array(s) with scattering agents administered to selected tissue that preferentially increase valley dose (69) within target to approximate broad beam. The methods of interleaving microbeams are also applied to treat diseases and conditions by ablating at least a portion of selected tissue, or by damaging blood-brain barrier for efficient drug and/or cell administration. A system for performing interlaced microbeam radiosurgery preferably includes two orthogonal radiation source arms (102) for producing and interleaving microbeam arrays (30,36) at the target volume (10). The methods treat tumors, pain, epilepsy, and neurological diseases.

Methods of treating MDS, or ameliorating a symptom thereof, are disclosed. Specific methods encompass the administration of one or more vitamin D compounds, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with one or more additional active agents. Other methods include intermittent administration of a high dose of one or more vitamin D compounds, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with one or more additional active agents. Such intermittent administration allows high doses of the vitamin D compounds to be administered while minimizing or eliminating hypercalcemia.

An exhaust system includes a first SCR catalyst and a second SCR catalyst positioned downstream of the first SCR catalyst. A first injector is provided upstream of the first SCR catalyst, and a second injector is provided upstream of the second SCR catalyst. The exhaust system further includes a gaseous ammonia supply device fluidly connected to the first injector for supplying gaseous ammonia to the exhaust gas by the first injector, and an ammonia-containing reductant reservoir fluidly connected to the second injector for supplying a fluid ammonia-containing reductant, such as urea, to the exhaust gas by the second injector. The first SCR catalyst has a smaller volume than the second SCR catalyst for a fast warm-up of the first SCR catalyst.

A process for treating an aqueous liquid. The process includes: passing the liquid by force of gravity through a treatment area, the liquid having an upper surface exposed to ambient pressure; disrupting the flow of the liquid as it passes through the treatment area, and exposing the upper surface of the liquid as the flow is disrupted to UV light. Disrupting the flow includes directing lower portions of the liquid toward the surface of the liquid to bring such portions into contact with UV light. A process for treating an aqueous liquid in which the treatment process is monitored. This process includes passing the liquid through a treatment area to bring the liquid into contact with reflective walls submerged below an upper surface of the liquid, and exposing the upper surface of the liquid to light emitted from a UV light source such that UV light penetrates the liquid to strike the submerged reflective surfaces and to be reflected therefrom to emerge through the upper surface of the liquid. The process also involves determining the intensity of the UV light emitted from the light source, determining the intensity of UV light received by a UV light sensor trained to receive emergent light and determining whether the treatment has a predetermined effectiveness based on the intensity of the UV light emitted from the light source and the intensity of the UV light received by the sensor. Apparatuses for carrying out processes of the invention are also described.

An imaging system includes an x-ray source coupled to a gantry. The x-ray source generates an x-ray flux, wherein a portion of the x-ray flux becomes scatter radiation. A scatter detector is also coupled to the gantry to receive the scatter radiation. The scatter detector generates a scatter signal in response to the scatter radiation, and a host computer receives the scatter signal.

The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration.

The present invention provides a system, method and apparatus for treating a liquid by providing a wave energy source and creating a thin film of the liquid whirling around the wave energy source such that one or more wave energies irradiate the liquid. Likewise, the present invention provides a method of treating a liquid by providing three zones of wave energy and passing the liquid through the three zones of wave energy.

Microprojection members (10) having a reservoir containing an antigenic agent and methods of using such members to vaccinate mammals (e.g., humans) are disclosed. The microprojection members are used to transdermally deliver an antigenic agent (e.g., a vaccine antigen) with substantially reduced skin reactions. This is achieved by delivering an induction amount and thereafter delivering one or more subsequent booster amounts. The induction amount is relatively larger than the booster amount. This technology has broad applicability for a wide variety of therapeutic vaccines to improve efficacy and convenience of use.

Methods for treating a coronary risk factor (such as hypertension, diabetes, hyperlipidemia and obesity) and/or a respiratory disorder (such as asthma, chronic obstructive pulmonary disease and bronchitis) and/or arthritis by local administration of a botulinum neurotoxin to at least one of a head, neck or shoulder location (for example, by subdermal, subcutaneous or intramuscular administration of the botulinum neurotoxin) of a patient with a coronary risk factor, respiratory disorder or arthritis.